At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
PF-04360365 10 mg/kg +2 morebiological
Likely dose
PF-04360365 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER'S DISEASE PATIENTS
In Brief
A Phase 2 clinical trial evaluating PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 36 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartAug 2009
Primary CompletionJun 2011
TodayJul 2026
First PostedJul 24, 2009
Enrollment StartAug 6, 2009
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.9 years ago
Interventions
PF-04360365 10 mg/kgbiological
10 mg/kg every 90 days (5 total doses)
PF-04360365 7.5 mg/kgbiological
10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
placebodrug
placebo administered every 90 days or monthly to match experimental treatment arms.